BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 25011056)

  • 21. Effects of tubastatin A on adrenocorticotropic hormone synthesis and proliferation of AtT-20 corticotroph tumor cells.
    Hagiwara R; Kageyama K; Iwasaki Y; Niioka K; Daimon M
    Endocr J; 2022 Sep; 69(9):1053-1060. PubMed ID: 35296577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
    Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
    Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.
    Jin K; Ruan L; Pu J; Zhong A; Wang F; Tan S; Huang H; Mu J; Yang G
    Mol Cell Endocrinol; 2018 Dec; 478():53-61. PubMed ID: 30025915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
    Schmid HA; Silva AP
    J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity.
    Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triptolide suppresses growth and hormone secretion in murine pituitary corticotroph tumor cells via NF-kappaB signaling pathway.
    Li R; Zhang Z; Wang J; Huang Y; Sun W; Xie R; Hu F; Lei T
    Biomed Pharmacother; 2017 Nov; 95():771-779. PubMed ID: 28892788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pituitary corticotrope cells: involvement of up-regulation of BMP receptor signaling by somatostatin analogs.
    Tsukamoto N; Otsuka F; Miyoshi T; Yamanaka R; Inagaki K; Yamashita M; Otani H; Takeda M; Suzuki J; Ogura T; Iwasaki Y; Makino H
    Endocrinology; 2010 Mar; 151(3):1129-41. PubMed ID: 20056821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mimecan in pituitary corticotroph cells may regulate ACTH secretion and the HPAA.
    Ma QY; Zhang XN; Jiang H; Wang ZQ; Zhang HJ; Xue LQ; Chen MD; Song HD
    Mol Cell Endocrinol; 2011 Jul; 341(1-2):71-7. PubMed ID: 21664248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
    Hofland LJ; van der Hoek J; van Koetsveld PM; de Herder WW; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; Feelders R; van der Lely AJ; Beckers A; Lamberts SW
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas.
    Morris DG; Kola B; Borboli N; Kaltsas GA; Gueorguiev M; McNicol AM; Ferrier R; Jones TH; Baldeweg S; Powell M; Czirják S; Hanzély Z; Johansson JO; Korbonits M; Grossman AB
    J Clin Endocrinol Metab; 2003 Dec; 88(12):6080-7. PubMed ID: 14671214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
    Lu J; Chatain GP; Bugarini A; Wang X; Maric D; Walbridge S; Zhuang Z; Chittiboina P
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2825-2835. PubMed ID: 28505327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.
    Araki T; Wang J; Lawrence R; Kawakami Y
    Endocrinology; 2022 Aug; 163(8):. PubMed ID: 35678423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effects of Smad3 on Adrenocorticotropic Hormone-Secreting Pituitary Adenoma Development, Cell Proliferation, Apoptosis, and Hormone Secretion.
    Zhou YZ; Li CZ; Gao H; Zhang YZ
    World Neurosurg; 2018 Jun; 114():e329-e337. PubMed ID: 29524699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
    Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
    Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
    Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
    Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.
    Gentilin E; Borges De Souza P; Ambrosio MR; Bondanelli M; Gagliardi I; Zatelli MC
    J Endocrinol Invest; 2023 Dec; 46(12):2609-2616. PubMed ID: 37233978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.